Ionis· @ionispharma · X·· 8 天前精选AI 评分68
AI 导读
Ionis与合作伙伴Otsuka宣布，评估一款在研RNA靶向药物治疗由FUS基因突变所致肌萎缩侧索硬化（ALS）的III期FUSION研究取得阳性顶线结果。相关详情见Ionis投资者关系页面发布的新闻稿。
推荐理由
Ionis与Otsuka公布FUS突变型ALS的RNA靶向药物III期FUSION研究阳性顶线结果，读者可了解该罕见病靶向疗法的关键进展。
正文
Today w/ partner Otsuka we announced positive topline results from the Ph3 FUSION study evaluating an investigational RNA-targeted medicine for people w/ amyotrophic lateral sclerosis (#ALS) caused by mutations in the fused in sarcoma (FUS) gene: https://ir.ionis.com/news-releases/news-release-details/ionis-announces-positive-topline-results-phase-3-fusion-study
$IONS
来源：Ionis · x.com